American Journal of Cardiology
Volume 104, Issue 4 , Pages 548-553 , 15 August 2009

Correlation of Non–High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol With Apolipoprotein B During Simvastatin + Fenofibrate Therapy in Patients With Combined Hyperlipidemia (A Subanalysis of the SAFARI Trial)

  • Scott M. Grundy, MD, PhD

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, Texas
    • Corresponding Author InformationCorresponding authors: Tel: (214) 648-2890; fax: (214) 648-4837
    • ,
  • Gloria Lena Vega, PhD

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, Texas
    • Corresponding Author InformationCorresponding authors: Tel: (214) 648-2890; fax: (214) 648-4837
    • ,
  • Joanne E. Tomassini, PhD

      Affiliations

    • Merck and Company, Incorporated, North Wales, Pennsylvania
    • ,
  • Andrew M. Tershakovec, MD, MPH

      Affiliations

    • Merck and Company, Incorporated, North Wales, Pennsylvania

Received 23 December 2008 ,Revised 8 April 2009 ,Accepted 8 April 2009.

References 

  1. National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  2. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  3. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology foundation. Diab Care. 2008;31:811–822
  4. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002;106:2526–2529
  5. Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551–556
  6. Clarenbach JJ, Grundy SM, Palacio N, Vega GL. Relationship of apolipoprotein B levels to the number of risk factors for metabolic syndrome. J Invest Med. 2007;55:237–247
  7. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome—an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  8. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J. 2003;169:921–924
  9. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diab Care. 2005;28:1916–1921
  10. Maki KC, Galant R, Davidson MH. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol. 2005;96:59K–64K
  11. Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002–3009
  12. Packard CJ, Saito Y. Non-HDL cholesterol as a measure of atherosclerotic risk. J Atheroscler Thromb. 2004;11:6–14
  13. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, et al. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006;259:247–258
  14. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003;361:777–780
  15. Stein EA, Sniderman A, Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol. 2005;96:36K–43K
  16. Sniderman AD, Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol. 2003;91:1173–1177
  17. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375–3383
  18. Simon A, Chironi G, Gariepy J, Del Pino M, Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis. 2005;179:339–344
  19. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol. 2001;88:265–269
  20. Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients—the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) trial. J Am Coll Cardiol. 2008;52:626–632
  21. LeRoux G, Lemieux I, Lamarche B, Cantin B, Dagenais GR, Lupien PJ, et al. Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-I levels. Metabolism. 2000;49:53–61
  22. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413–1419
  23. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95:462–468
  24. Smith SJ, Cooper GR, Henderson LO, Hannon WH. An international collaborative study on standardization of apolipoprotein A-I and apolipoprotein B: part I (Evaluation of a lyophilized candidate reference and calibration material). Clin Chem. 1987;33:2240–2249
  25. Young SG, Smith RS, Hogle DM, Curtiss LK, Witztum JL. Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. Clin Chem. 1986;32:1484–1490
  26. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326–333
  27. Sniderman AD, Hogue JC, Bergeron J, Gagne C, Couture P. Non-HDL cholesterol and apoB in dyslipidaemia. Clin Sci Lond. 2008;114:149–155
  28. Albers JJ, Adolphson JL. Comparison of commercial kits for apoprotein-A-I and apoprotein-B with standardized apoprotein-A-I and B radioimmunoassays performed at the Northwest Lipid Research Center. J Lipid Res. 1988;29:102–108
  29. Beghin L, Duhal N, Poulain P, Hauw P, Lacroix B, Lecerf JM, et al. Measurement of apolipoprotein B concentration in plasma lipoproteins by combining selective precipitation and mass spectrometry. J Lipid Res. 2000;41:1172–1176
  30. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoprotein-A-I and apolipoprotein-B (Part IV. Comparability of apolipoprotein-B values by use of international reference material). Clin Chem. 1994;40:586–592

 The original SAFARI trial was supported by Merck and Company, Incorporated, Whitehouse Station, New Jersey.

 Dr. Grundy's and Dr. Vega's research was supported in part by the Department of Veteran Affairs, Moss Heart Center, and Donald W. Reynolds Cardiovascular Research Center at Dallas, Texas.

 Drs. Tershakovec and Tomassini are employees of Merck and Company, Incorporated, North Wales, Pennsylvania, and own stock and stock options in the company.

PII: S0002-9149(09)00921-7

doi: 10.1016/j.amjcard.2009.04.018

American Journal of Cardiology
Volume 104, Issue 4 , Pages 548-553 , 15 August 2009

Article Tools

* Image Usage & Resolution